



Alan Farrell, T.D.  
Dáil Éireann,  
Leinster House,  
Kildare Street,  
Dublin 2.

1<sup>st</sup> April, 2021

PQ: 15426/21

**To ask the Minister for Health the status of efforts to approve dupilumab commonly known as dupixent used to treat eczema and asthma among other conditions; and if he will make a statement on the matter. -Alan Farrell.**

Dear Deputy Farrell,

The Health Service Executive has been requested to reply directly to you in the context of the above Parliamentary Question (Reference 15426/21), which you submitted to the Minister for Health for response.

Dupilumab is available for reimbursement under the High Tech arrangements from the 1<sup>st</sup> of April 2021 for moderate-to-severe atopic dermatitis in refractory adults and adolescents 12 years and older for whom immunosuppressant treatment has failed, or is not tolerated or is contraindicated.

The PCRS website has been updated accordingly: <https://www.sspcrs.ie/libr/html/monthlyproductupdate.pdf>

A Managed Access Protocol is in place for Dupilumab. The protocol outlines the criteria that must be satisfied in order for a patient to be recommended for reimbursement of Dupilumab under High Tech Arrangements. Further information on how this managed access protocol is implemented is available online: <https://www.hse.ie/eng/about/who/cspd/ncps/medicines-management/managed-access-protocols/dupilumab/>

The HSE has provided funding support for all pricing and reimbursement (P&R) applications that it has received for Dupilumab to date.

There are currently no ongoing applications for Dupilumab.

No P&R application for Dupilumab for the treatment of asthma has been submitted to the HSE from the manufacturer (Sanofi) as of the 1<sup>st</sup> of April 2021.

Yours sincerely,

Suzanne Doyle  
Primary Care Eligibility & Reimbursement Service